| Christopher M Corsi, MD | |
|
900 N Orange St Ste 304, Missoula, MT 59802-2951 | |
| (406) 329-5781 | |
| (406) 327-3331 |
| Full Name | Christopher M Corsi |
|---|---|
| Gender | Male |
| Speciality | Endocrinology |
| Experience | 38 Years |
| Location | 900 N Orange St Ste 304, Missoula, Montana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174577589 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 8765 (Montana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St. Patrick Hospital | Missoula, MT | Hospital |
| Steele Memorial Medical Center | Salmon, ID | Hospital |
| St Peters Hospital | Helena, MT | Hospital |
| Community Medical Center | Missoula, MT | Hospital |
| Marcus Daly Memorial Hospital - Cah | Hamilton, MT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Providence Health And Services Mt | 6608786306 | 272 |
News Archive
After three years in development, MedCure, Inc. has perfected a technique that mimics functioning circulatory system processes in cadaveric specimens.
Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).
Italian researchers have shown for the first time that it is possible to test a woman's egg, before fertilisation, for chromosomal abnormalities that might make an embryo less likely to implant successfully or more likely to miscarry at a later stage.
Many drugs commonly prescribed to older adults for a variety of common medical conditions including allergies, hypertension, asthma, and cardiovascular disease appear to negatively affect the aging brain causing immediate but possibly reversible cognitive impairment, including delirium, in older adults according to a clinical review now available online in the Journal of Clinical Interventions in Aging, a peer reviewed, open access publication.
› Verified 7 days ago
| Entity Name | Providence Health & Services Mt |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144319138 PECOS PAC ID: 6608786306 Enrollment ID: O20031229000787 |
News Archive
After three years in development, MedCure, Inc. has perfected a technique that mimics functioning circulatory system processes in cadaveric specimens.
Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).
Italian researchers have shown for the first time that it is possible to test a woman's egg, before fertilisation, for chromosomal abnormalities that might make an embryo less likely to implant successfully or more likely to miscarry at a later stage.
Many drugs commonly prescribed to older adults for a variety of common medical conditions including allergies, hypertension, asthma, and cardiovascular disease appear to negatively affect the aging brain causing immediate but possibly reversible cognitive impairment, including delirium, in older adults according to a clinical review now available online in the Journal of Clinical Interventions in Aging, a peer reviewed, open access publication.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher M Corsi, MD 900 N Orange St Ste 304, Missoula, MT 59802-2951 Ph: (406) 329-5781 | Christopher M Corsi, MD 900 N Orange St Ste 304, Missoula, MT 59802-2951 Ph: (406) 329-5781 |
News Archive
After three years in development, MedCure, Inc. has perfected a technique that mimics functioning circulatory system processes in cadaveric specimens.
Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).
Italian researchers have shown for the first time that it is possible to test a woman's egg, before fertilisation, for chromosomal abnormalities that might make an embryo less likely to implant successfully or more likely to miscarry at a later stage.
Many drugs commonly prescribed to older adults for a variety of common medical conditions including allergies, hypertension, asthma, and cardiovascular disease appear to negatively affect the aging brain causing immediate but possibly reversible cognitive impairment, including delirium, in older adults according to a clinical review now available online in the Journal of Clinical Interventions in Aging, a peer reviewed, open access publication.
› Verified 7 days ago
Mr. George Bandow, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 2809 Great Northern Loop, Suite 200, Missoula, MT 59808 Phone: 406-541-7139 Fax: 406-541-7143 | |
Simone Musco, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 500 W Broadway St, Ste 320, Missoula, MT 59802 Phone: 406-329-5615 | |
Rolf H O Holle, M.D. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 1782 Elison Ln Unit 3, Missoula, MT 59802 Phone: 406-544-1871 | |
John David Anthony Lakatua, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 500 West Broadway, Missoula, MT 59802 Phone: 406-721-5600 Fax: 406-721-3907 | |
Mr. Curtis G Wickre, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 500 W Broadway St, 4th Floor, Missoula, MT 59802 Phone: 406-327-1900 | |
Dr. Charlotte Nelson, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 500 W Broadway St, Missoula, MT 59802 Phone: 406-327-1613 | |
Michele A Danicich, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 900 N Orange St Ste 304, Missoula, MT 59802 Phone: 406-329-5781 Fax: 406-327-3331 |